Repligen (RGEN) Earnings Date, Estimates & Call Transcripts → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free rgen Stock Alerts $157.48 +0.34 (+0.22%) (As of 04/22/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 1Before Market OpensConfirmedActual EPS (Feb. 21) $0.33 Consensus EPS (Feb. 21) $0.33 Read Call TranscriptListen to Call Get Repligen Earnings AlertsEnter your email address below to receive the latest news and earnings results for RGEN and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRGEN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RGEN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Repligen Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20244$0.29$0.75$0.41 Q2 20244$0.31$0.83$0.45 Q3 20244$0.38$0.85$0.50 Q4 20244$0.44$0.91$0.56 FY 202416$1.42$3.34$1.92 Q1 20253$0.44$0.47$0.46 Q2 20253$0.48$0.50$0.49 Q3 20253$0.52$0.56$0.54 Q4 20253$0.54$0.61$0.57 FY 202512$1.98$2.14 $2.05RGEN Earnings Date and InformationRepligen last announced its earnings data on February 21st, 2024. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts' consensus estimates of $0.33. The company earned $155.74 million during the quarter, compared to analyst estimates of $155.38 million. Its revenue was down 16.6% on a year-over-year basis. Repligen has generated $0.72 earnings per share over the last year ($0.72 diluted earnings per share) and currently has a price-to-earnings ratio of 218.7. Earnings for Repligen are expected to grow by 43.15% in the coming year, from $1.46 to $2.09 per share. Repligen has confirmed that its next quarterly earnings report will be published on Wednesday, May 1st, 2024. Repligen will be holding an earnings conference call on Wednesday, May 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call. or dial in at 412-317-0088 with passcode "3623615". Read More Repligen Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/1/2024Confirmed)------- 2/21/2024Q4 2023$0.33$0.33-$1.12$155.38 million$155.74 million 10/31/2023Q3 2023$0.14$0.23+$0.09$0.14$140.68 million$141.20 million 8/2/2023Q2 2023$0.49$0.53+$0.04$0.71$165.93 million$159.20 million 5/2/2023Q1 2023$0.59$0.64+$0.05$0.77$181.43 million$182.70 million 2/22/2023Q4 2022$0.58$0.68+$0.10$0.51$184.41 million$186.80 million 11/1/2022Q3 2022$0.68$0.77+$0.09$0.83$192.01 million$200.74 million Get the Latest News and Ratings for RGEN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. 8/2/2022Q2 2022$0.72$0.91+$0.19$0.94$189.06 million$207.63 million 4/27/2022Q1 2022$0.72$0.92+$0.20$1.03$185.48 million$206.40 million 2/17/2022Q4 2021$0.65$0.81+$0.16$1.12$178.27 million$186.52 million 10/28/2021Q3 2021$0.64$0.78+$0.14$0.98$163.97 million$178.22 million 7/26/2021Q2 2021$0.52$0.79+$0.27$0.94$144.24 million$162.96 million 5/4/2021Q1 2021$0.42$0.68+$0.26$0.84$117.88 million$142.80 million Repligen Earnings - Frequently Asked Questions When is Repligen's earnings date? Repligen has confirmed that its next quarterly earnings data will be published on Wednesday, May 1st, 2024. Learn more on RGEN's earnings history. Did Repligen beat their earnings estimates last quarter? In the previous quarter, Repligen (NASDAQ:RGEN) reported $0.33 earnings per share (EPS) to hit the analysts' consensus estimate of $0.33. Learn more on analysts' earnings estimate vs. RGEN's actual earnings. How can I listen to Repligen's earnings conference call? The conference call for Repligen's latest earnings report can be listened to online. Listen to Conference Call How can I read Repligen's conference call transcript? The conference call transcript for Repligen's latest earnings report can be read online. Read Transcript How much revenue does Repligen generate each year? Repligen (NASDAQ:RGEN) has a recorded annual revenue of $638.76 million. How much profit does Repligen generate each year? Repligen (NASDAQ:RGEN) has a recorded net income of $41.58 million. RGEN has generated $0.72 earnings per share over the last four quarters. What is Repligen's price-to-earnings ratio? Repligen (NASDAQ:RGEN) has a trailing price-to-earnings ratio of 218.73 and a forward price-to-earnings ratio of 107.86. The price/earnings-to-growth ratio is 5.15. What is Repligen's EPS forecast for next year? Repligen's earnings are expected to grow from $1.46 per share to $2.09 per share in the next year, which is a 43.15% increase. More Earnings Resources from MarketBeat Related Companies: Exelixis Earnings Date Neurocrine Biosciences Earnings Date Halozyme Therapeutics Earnings Date Adaptive Biotechnologies Earnings Date Biogen Earnings Date Qiagen Earnings Date Bio-Techne Earnings Date Vaxcyte Earnings Date Revolution Medicines Earnings Date CRISPR Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Taiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted Applied Optoelectronics earnings dumper, pain now for gain later? This page (NASDAQ:RGEN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.